99471-66-6

Usage

Uses

Used in Pharmaceutical Industry:
(E)-3-Ethoxyacryloyl chloride is used as a synthetic reagent for the production of various pharmaceutical compounds. Its reactivity allows for the creation of new molecules with potential therapeutic properties, contributing to the development of novel drugs.
Used in Agrochemical Industry:
In the agrochemical sector, (E)-3-Ethoxyacryloyl chloride serves as a key intermediate in the synthesis of pesticides and other agricultural chemicals. Its ability to undergo multiple chemical reactions enables the production of a variety of bioactive molecules for crop protection and enhancement.
Used in Synthetic Materials Industry:
(E)-3-Ethoxyacryloyl chloride is employed as a building block in the synthesis of synthetic materials, such as polymers and resins. Its versatility in chemical reactions facilitates the development of new materials with specific properties for various applications, including coatings, adhesives, and composites.

Upstream product

• 6192-01-4 (E)-3-ethoxyprop-2-enoic acid 
• 6191-97-5 3,3-diethoxypropanoic acid 
• 75-44-5 phosgene 
• 124-38-9 carbon dioxide 
• 109-92-2 ethyl vinyl ether 
• 79-37-8 oxalyl dichloride 
• 59938-07-7 (3E)-1,1,1-trichloro-4-ethoxybut-3-en-2-one 
• 5941-55-9 ethyl 3-ethoxyacrylate 
• 10601-80-6 ethyl 3,3-diethoxypropanoate 
• 144874-96-4 (E)-4-ethoxy-2-oxo-3-butenoyl chloride 

Downstream Products

• 5941-55-9 ethyl 3-ethoxyacrylate 
• 61349-92-6 (3t-ethoxy-acryloyl)-carbamic acid ethyl ester 
• 100135-45-3 N-(3t-ethoxy-acryloyl)-N'-phenyl-urea 
• 100138-81-6 4-(3t-ethoxy-acryloyl)-1-phenyl semicarbazide 
• 6192-01-4 (E)-3-ethoxyprop-2-enoic acid 
• 105786-78-5 3-Ethoxyacrylsaeure-3-methoxyphenylester 
• 487-06-9 Limettin 
• 105786-71-8 3-Ethoxyacrylsaeure-4-nitrophenylester 
• 105786-72-9 3-Ethoxy-3-(4-nitrophenoxy)propansaeure-4-nitrophenylester 
• 105786-77-4 3-Ethoxyacrylsaeure-3-chlorphenylester 
• 105786-80-9 3-Ethoxyacrylsaeure-2-chlorphenylester 
• 99465-19-7 (E)-N-(4-Bromo-3-methyl-phenyl)-3-ethoxy-acrylamide 
• 99465-23-3 (E)-N-(4-Bromo-2-methoxy-phenyl)-3-ethoxy-acrylamide 
• 115983-78-3 (E)-3-ethoxypropenoyl isocyanate 

Relevant academic research and scientific papers

REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-A]PYRIMIDINES

A method of regio-selectively synthesizing an imidazo-pyrimidine compound of formulae (XXa) or (XXb) comprising a step of coupling a first compound of formula XX-P1a or XX-P1b with a second compound of formula XX-P2. This annulation reaction between β-ethoxy acrylamides and phosphorylated aminoimidazoles to furnish imidazo[1,2-a]pyrimidin-amines relies on steering effects from endocyclic and exocyclic phosphorylated aminoimidazoles. The reaction furnishes either 2-amino or 4-amino constitutional isomers of imidazo[1,2-a]pyrimidines with good yields and ranges of 90:10 – 99:1 regio-selectivity. The reaction is useful in the synthesis of various tracer molecules used in the study of neurological conditions such as where R3 and R4 together with the imidazole ring atoms to which they are bonded form a phenyl ring and the products are substituted benzimidazopyrimidines. The reaction can be generalized to form imidazo[1,2-a]pyrimidines substituted at either of their 2- and 4- positions by alkoxy or thioalkyl groups.

Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates

The synthesis of both 2?-hydroxy-3?-deoxy and 2?-deoxy-3?-hydroxy cyclopentyl nucleoside phosphonates with the natural nucleobases adenine, thymine, cytosine and guanine from a single precursor has been performed. The guanine containing analogues showed antiviral activity. Especially the 3?-deoxy congener 23 was active, displaying an EC50 of 5.35 μM against TK+ VZV strain and an EC50 of 8.83 μM against TK? VZV strain, besides lacking cytotoxicity. However, the application of phosphonodiamidate prodrug strategy did not lead to a boost in antiviral activity.

HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF

The present disclosure relates to compounds of Formula I, or their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.

INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE

The present disclosure is directed to compounds of formula I and methods of their use and preparation, as well as compositions comprising compounds of formula I.

Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins

The bromodomain and plant homeodomain finger-containing (BRPF) family are scaffolding proteins important for the recruitment of histone acetyltransferases of the MYST family to chromatin. Here, we describe NI-57 (16) as new pan-BRPF chemical probe of the bromodomain (BRD) of the BRPFs. Inhibitor 16 preferentially bound the BRD of BRPF1 and BRPF2 over BRPF3, whereas binding to BRD9 was weaker. Compound 16 has excellent selectivity over nonclass IV BRD proteins. Target engagement of BRPF1B and BRPF2 with 16 was demonstrated in nanoBRET and FRAP assays. The binding of 16 to BRPF1B was rationalized through an X-ray cocrystal structure determination, which showed a flipped binding orientation when compared to previous structures. We report studies that show 16 has functional activity in cellular assays by modulation of the phenotype at low micromolar concentrations in both cancer and inflammatory models. Pharmacokinetic data for 16 was generated in mouse with single dose administration showing favorable oral bioavailability.

High-affinity recognition of the human C-reactive protein independent of phosphocholine

A high-affinity polypeptide conjugate 4-C25L22-DQ, has been developed for the molecular recognition of the human C-reactive protein, CRP, a well-known inflammation biomarker. CRP is one of the most frequently quantified targets in diagnostic applications and a target in drug development. With the exception of antibodies, most molecular constructs take advantage of the known affinity for CRP of phosphocholine that depends on Ca2+ for its ability to bind. 4-C25L22-DQ which is unrelated to phosphocholine binds in the absence of Ca2+ with a dissociation constant of 760 nM, an order of magnitude lower than that of phosphocholine, the KD of which is 5 μM. The small organic molecule 2-oxo-1,2-dihydroquinoline-8-carboxylic acid (DQ) was designed based on the structural similarities between three hits from a set of compounds selected from a building block collection and evaluated with regards to affinity for CRP by NMR spectroscopy. 4-C25L22-DQ was shown in a competition experiment to bind CRP three orders of magnitude more strongly than DQ itself, and in a pull-down experiment 4-C25L22-DQ was shown to extract CRP from human serum. The development of a robust and phosphocholine-independent recognition element provides unprecedented opportunities in bioanalytical applications in vivo and in vitro under conditions where the concentration of Ca2+ ions is low, or where Ca2+ binding agents such as EDTA or heparin are needed to prevent blood coagulation. The identification from a compound library of a small organic molecule and its conjugation to a small set of polypeptides, none of which were previously known to bind CRP, illustrates a convenient and general route to selective high-affinity binders for proteins with dissociation constants in the μM to nM range for which no small molecule ligands are known.

CRYSTALLINE FORMS OF N-(2-CHLORO-6-METHY]PHENVN-2-[F6-[4-(2-HVDROXVETHVL)-L- PIPERAZINVIL-2-METHVL-4-PVRIMIDINVLLAMINOL-5-THIAZOLECARBOXAMIDE AND THEIR PROCESS THEREOF

The present invention relates to crystalline 1,2-Propanediol solvate of N-(2-chloro-6- methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-l-piperazinyl]-2-methyl-4-pyrimidinyl]ainino]-5- thiazolecarboxamide compound of formula- lb, its process for the preparation and its use in the preparation of anhydrous crystalline form (N-6) and monohydrate of N-(2-chloro-6- methy lphenyl)-2- [ [6- [4-(2 -hydroxy ethyl)- 1 -piperazinyl] -2-methyl-4-pyrimidinyl]amino] -5 - thiazolecarboxamide. [formula] 1,2-Propanediol solvate Formula- lb

PROCESSES FOR THE PREPARATION OF IVACAFTOR

The present invention provides processes for the preparation of ivacaftor using novel intermediates and a process for its preparation.

Six-membered c-n-linked aryl sulfide derivatives and aryl sulfoxide derivatives as pest control agents

The present application relates to new heterocyclic compounds of formula (I), wherein D stands for a substructure of formula (I-A), a method for the production thereof and the use thereof for combatting animal pests, including arthropods and in particular insects and acarides.

Design, synthesis, and protein crystallography of biaryltriazoles as potent tautomerase inhibitors of macrophage migration inhibitory factor

Optimization is reported for biaryltriazoles as inhibitors of the tautomerase activity of human macrophage migration inhibitory factor (MIF), a proinflammatory cytokine associated with numerous inflammatory diseases and cancer. A combined approach was taken featuring organic synthesis, enzymatic assaying, crystallography, and modeling including free-energy perturbation (FEP) calculations. X-ray crystal structures for 3a and 3b bound to MIF are reported and provided a basis for the modeling efforts. The accommodation of the inhibitors in the binding site is striking with multiple hydrogen bonds and aryl-aryl interactions. Additional modeling encouraged pursuit of 5-phenoxyquinolinyl analogues, which led to the very potent compound 3s. Activity was further enhanced by addition of a fluorine atom adjacent to the phenolic hydroxyl group as in 3w, 3z, 3aa, and 3bb to strengthen a key hydrogen bond. It is also shown that physical properties of the compounds can be modulated by variation of solvent-exposed substituents. Several of the compounds are likely the most potent known MIF tautomerase inhibitors; the most active ones are more than 1000-fold more active than the well-studied (R)-ISO-1 and more than 200-fold more active than the chromen-4-one Orita-13.